Around $15M Bet On Taysha Gene Therapies? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying

The Dow Jones closed lower by around 180 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Taysha Gene Therapies

• The Trade: Taysha Gene Therapies, Inc. TSHA 10% owner Paul Manning acquired a total of 16,466,667 shares an average price of $0.90. To acquire these shares, it cost around $14.82 million. The company’s other executives also purchased the company’s shares.
• What’s Happening: Taysha Gene Therapies reported initial clinical data from the first adult Rett Syndrome patient dosed in the REVEAL Phase 1/2 trial and announced $150 million private placement financing.
• What Taysha Gene Therapies Does: Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations.

Amarin

• The Trade: Amarin Corporation plc AMRN President and CEO Patrick Holt acquired a total of 300,000 shares at an average price of $1.04. The insider spent around $312,315.
• What’s Happening: Amarin posted a profit for the second quarter.
• What Amarin Does: Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its lead product includes Vascepa.

Rapid Micro Biosystems

• The Trade: Rapid Micro Biosystems, Inc. RPID President and CEO Robert G. Spignesi, Jr. acquired a total of 20,000 shares at an average price of $0.97. To acquire these shares, it cost around $19,488.
• What’s Happening: Rapid Micro Biosystems posted a narrower-than-expected quarterly loss.
• What Rapid Micro Biosystems Does: Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables.

Check This Out: Top 5 Consumer Stocks That May Fall Off A Cliff

Don’t forget to check out our premarket coverage here

Indaptus Therapeutics

• The Trade: Indaptus Therapeutics, Inc. INDP 10% owner Glen R Anderson acquired a total of 103,352 shares at an average price of $2.09. The insider spent $216,388 to buy those shares.
• What’s Happening: Indaptus Therapeutics posted a narrower-than-expected quarterly loss.
• What Indaptus Therapeutics Does: Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy.